Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB017 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis
NCT03958877Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Oct 2019
- Primary completion
- May 2027
- Modality
- Interferons
- Countries
- 22
01
Overview
A Phase 3 trial of peginterferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Started Oct 2019; status: active, not recruiting.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03958877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958877.